Table 1 Baseline characteristics by outcome group.
All | Favourable neurological outcome | Unfavourable neurological outcome | |
|---|---|---|---|
n = 832 | n = 357 | n = 475 | |
Age, median (IQR) | 60 (49–70) | 55 (47–66) | 63 (51–73) |
Female, n (%) | 236 (28) | 92 (26) | 144 (30) |
Witnessed, n (%) | 691 (83) | 323 (90) | 368 (78) |
BLS, n (%) | 505 (61) | 239 (67) | 266 (56) |
Initial rhythm, n (%) | |||
VT | 4 (1) | 3 (0.8) | 1 (0.2) |
VF | 440 (53) | 257 (72) | 183 (39) |
PEA | 191 (23) | 50 (14) | 141 (30) |
Asystole | 133 (16) | 14 (4) | 119 (25) |
Unknown | 63 (8) | 32 (9) | 31 (7) |
No Flow (min), median (IQR)a | 0 (0–1) | 0 (0–1) | 0 (0–1) |
Low Flow (min), median (IQR)a | 23 (14–37) | 16 (10–25) | 29 (20–48) |
Origin, n (%) | |||
Pulmonary | 114 (14) | 26 (7) | 88 (19) |
Cardiac | 547 (66) | 284 (79) | 263 (55) |
Metabolic | 11 (1) | 4 (1) | 7 (2) |
Intoxication | 25 (3) | 5 (1) | 20 (4) |
Drowning | 15 (2) | 4 (1) | 11 (2) |
Sepsis | 1 (0.1) | 0 (0) | 1 (0.2) |
Other | 18 (2) | 3 (1) | 15 (3) |
Cerebral | 34 (4) | 5 (1) | 29 (6) |
Unknown | 67 (8) | 26 (7) | 41 (9) |
Total dose of epinephrine in mg, median (IQR) | 2 (0–4) | 0 (0–2) | 3 (1–5) |
Number of shocks applied, median (IQR)b | 3 (1–6) | 3 (1–5) | 4 (2–7) |
pH, median (IQR) | 7.16 (7.02–7.27) | 7.24 (7.12–7.30) | 7.10 (6.95–7.31) |
Lactate (mmol/l), median (IQR) | 7.3 (4.3–10.8)) | 5.1 (3.0–8.1) | 8.9 (6.2–12.1) |
CRP (mg/dl), median (IQR) | 0.33 (0.14–0.94) | 0.26 (0.11–0.62) | 0.44 (0.15–1.46) |
Chronic health conditions, n (%) | |||
Diabetes | 158 (19) | 49 (14) | 109 (23) |
Hypertension | 339 (41) | 122 (34) | 217 (46) |
Current smoker | 239 (29) | 115 (32) | 124 (26) |
Chronic heart failure | 89 (11) | 31 (9) | 58 (12) |
Myocardial infarction | 89 (11) | 38 (11) | 51 (11) |
Cerebral vascular insufficiency | 53 (6) | 15 (4) | 38 (8) |
Coronary artery disease | 163 (20) | 66 (19) | 97 (20) |
Chronic obstructive pulmonary disease | 105 (13) | 34 (10) | 71 (15) |
